Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Mitapivat (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ESTIMATE
- 12 Dec 2023 Results of the safety and efficacy of treatment with mitapivat in patients with SCD from the 1-year fixed-dose extension period , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results (n=9) assessing pre-specified safety and efficacy data of the 1-year fixed-dose extension period (FDEP) ofmitapivat treatment in subjects with SCD, presented at the 28th Congress of the European Haematology Association.
- 11 May 2023 According to an Agios Pharmaceuticals Media Release, data from this trial will be presented at the 2023 European Hematology Association (EHA) Annual Meeting.